Zobrazeno 1 - 10
of 117
pro vyhledávání: '"11"'
Autor:
Charlène Duboc, Laurent Poulain, Marie-Hélène Louis, Edwige Abeilard, Marie Villedieu, Christophe Denoyelle, Pascal Gauduchon, Cécile Pétigny-Lechartier, Abdelghani Jebahi
Publikováno v:
Molecular Cancer Therapeutics. 16:102-115
The identification of novel therapeutic strategies is an important urgent requirement for the clinical management of ovarian cancer, which remains the leading cause of death from gynecologic cancer. Several studies have shown that the antiapoptotic p
Autor:
Reuven Agami
Publikováno v:
Molecular Cancer Therapeutics. 12:CN01-03
The past decade has witnessed a swift advance in the identification of microRNAs and elucidation of their function. In particular, miRNAs were found to present cancer-specific expression patterns, but also to encompass causative roles in cancer devel
Autor:
G. Sánchez-Ollé, Claudia Aura, Elena Elez, Danila Serpico, Ana Vivancos, Teresa Macarulla, Ludmila Prudkin, Stefania Landolfi, Maria Alsina, Jose Perez-Garcia, Jaume Capdevila, Jordi Rodon, Cristina Saura, Josep Tabernero, Rodrigo Dienstmann, Javier Hernández-Losa
Publikováno v:
Molecular cancer therapeutics. 11(9)
Clinical experience increasingly suggests that molecular prescreening and biomarker enrichment strategies in phase I trials with targeted therapies will improve the outcomes of patients with cancer. In keeping with the exigencies of a personalized on
Autor:
Elvira Buxo, Jordi Codony-Servat, Raquel Bermudo, Pedro Gascón, Mercedes Marín-Aguilera, Begoña Mellado, Susana G. Kalko, Maria J. Ribal, Pedro L. Fernández
Publikováno v:
Molecular cancer therapeutics. 11(2)
Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer (CRPC). However, most patients eventually develop resistance to this treatment. In this study, we aimed to identify key molecular genes
Abstract CN02-03: Targeted multiplexed DNA sequencing for biomarker discovery and clinical diagnosis
Autor:
Michael F. Berger
Publikováno v:
Molecular Cancer Therapeutics. 12:CN02-03
Massively parallel sequencing technology has catalyzed the discovery of genetic alterations that drive tumor initiation and progression. Efforts to comprehensively characterize the genomes of the most common tumor types have revealed recurrent altera
Autor:
Ovidiu Balacescu, Oana Tudoran, Olga Soritau, Staffan Lindberg, Ioana Berindan-Neagoe, Loredana Balacescu
Publikováno v:
Molecular Cancer Therapeutics. 12:C6-C6
Cervical cancer was reported to be the second most common female cancer worldwide, being the third cause of female cancer mortality annually. Romania ranks first among European countries in cervical cancer incidence and mortality raising the national
Autor:
Florian Markowetz
Publikováno v:
Molecular Cancer Therapeutics. 12:PL05-03
Intra-tumor genetic heterogeneity is the result of ongoing evolutionary change within each cancer. The expansion of genetically distinct sub-clonal populations may explain the emergence of drug resistance and if so would have prognostic and predictiv
Autor:
Roz Brant, Tom Liptrot, Darren Hodgson, Carl Barrett, Elizabeth A. Harrington, Paul D. Smith, Jonathan R. Dry
Publikováno v:
Molecular Cancer Therapeutics. 12:A209-A209
Inhibition of the RAS-RAF-MEK axis holds significant promise for targeted cancer therapy, highlighted by the recent clinical approval of BRAF (vemurafenib) and MEK (trametinib) inhibitors, and ongoing late-stage clinical trials for several other MEK
Publikováno v:
Molecular Cancer Therapeutics. 12:A236-A236
Triple negative breast cancer (TNBC) accounts for 20% of breast cancer in women and lacks an effective targeted therapy. Therefore, finding common vulnerabilities in these tumors represents an opportunity for more effective treatment. Recent large-sc
Autor:
Gilfillan Siv, Sandra Lopez, Anne Lise Børresen-Dale, Toni Hurtado, Ruthmma Martin, Madhumohan R. Katika
Publikováno v:
Molecular Cancer Therapeutics. 12:B124-B124
Breast cancer cell proliferation results from many different factors that activate multiple cellular signaling pathways, which are currently target therapies. Yet, how genomic pathways are influenced upon cell-signaling disruption has been poorly ass